MTH1
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S7505 | (S)-crizotinib | <1 mg/mL | 42 mg/mL | 22 mg/mL |
| S7631 | TH287 | <1 mg/mL | 53 mg/mL | 10 mg/mL |
| S7632 | TH588 | <1 mg/mL | 20 mg/mL | 1 mg/mL |
MTH1产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7505 |
(S)-crizotinib(S)-crizotinib，crizotinib的(S)型异构体，是一种有效的MTH1 (NUDT1)抑制剂，无细胞试验中IC50为72 nM。 |
-crizotinib-S750501W0220161111.gif)
-crizotinib-S750501W0220161111.gif)
(B) Inhibition of ALK phosphorylation by alectinib in the Ba/F3 cell lines expressing mutated EML4-ALK. Cells were treated with alectinib or crizotinib for 2 h at the indicated concentrations. Phosphorylated ALK (Tyr 1604), ALK, and β-actin were detected by immunoblot analysis using antibodies to each of them.
|
|
| S7631 |
TH287TH287是一种有效的选择性 MTH1 (NUDT1) 抑制剂，IC50 为 0.8 nM。 |
||
| S7632 |
TH588TH588是一种有效的选择性MTH1 (NUDT1)抑制剂，IC50为5 nM。在浓度为100 μM时，对所检测的其他蛋白没有相关抑制作用，但是在10 μM时，对另外一些酶、GPCRs、激酶、离子通道和转运体有一定的选择性。 |
Square wave voltammograms of C-DNA modified gold electrodes after incubation with different reaction solution that contains (a) active MTH1 (1.0 mg/mL), (b) inactivated MTH1 (1.0 mg/mL), (c) active MTH1 (1.0 mg/mL) with 10 μM TH588 inhibitor, and (d) hOGG1 (5.0 units).
|
-crizotinib-Onco-Targets-Ther-20170112.gif)
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7505 |
(S)-crizotinib(S)-crizotinib，crizotinib的(S)型异构体，是一种有效的MTH1 (NUDT1)抑制剂，无细胞试验中IC50为72 nM。 |
(B) Inhibition of ALK phosphorylation by alectinib in the Ba/F3 cell lines expressing mutated EML4-ALK. Cells were treated with alectinib or crizotinib for 2 h at the indicated concentrations. Phosphorylated ALK (Tyr 1604), ALK, and β-actin were detected by immunoblot analysis using antibodies to each of them.
|
|
| S7631 |
TH287TH287是一种有效的选择性 MTH1 (NUDT1) 抑制剂，IC50 为 0.8 nM。 |
||
| S7632 |
TH588TH588是一种有效的选择性MTH1 (NUDT1)抑制剂，IC50为5 nM。在浓度为100 μM时，对所检测的其他蛋白没有相关抑制作用，但是在10 μM时，对另外一些酶、GPCRs、激酶、离子通道和转运体有一定的选择性。 |
Square wave voltammograms of C-DNA modified gold electrodes after incubation with different reaction solution that contains (a) active MTH1 (1.0 mg/mL), (b) inactivated MTH1 (1.0 mg/mL), (c) active MTH1 (1.0 mg/mL) with 10 μM TH588 inhibitor, and (d) hOGG1 (5.0 units).
|
